Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Biologics and Biosimilar), Source (Microbial and Mammalian), Application (Commercial and Clinical), and Therapeutic Area (Oncology, Autoimmune Disorders, Respiratory Disorders, Metabolic Disorders, Neurology, Infectious Diseases, and Others)
The Middle East & Africa Biopharmaceutical Contract Manufacturing Market is poised for significant growth, with projections indicating an increase from US$ 875.4 million in 2024 to US$ 1,655.0 million by 2031. This growth trajectory reflects a compound annual growth rate (CAGR) of 9.3% from 2025 to 2031, driven by various factors including rising healthcare investments, an increasing prevalence of chronic diseases, and initiatives aimed at enhancing local pharmaceutical manufacturing capabilities.
The market is primarily segmented into key regions: the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa (MEA). Among these, the UAE and Saudi Arabia are at the forefront, showcasing robust infrastructure development and attracting substantial foreign direct investment. South Africa is also making strides through public-private partnerships, such as its collaboration with Biovac, a local vaccine manufacturer, which aims to bolster domestic production capabilities.
A notable trend in the biopharmaceutical contract manufacturing sector is the growing demand for biologics and biosimilars. As regional pharmaceutical companies face limitations in their in-house manufacturing capabilities, there is a marked shift towards outsourcing production to contract manufacturers. This outsourcing trend is further fueled by the increasing need for innovative therapies, including monoclonal antibodies, gene therapies, and cell-based treatments, which necessitate advanced manufacturing processes.
The market segmentation reveals that, by product type, biologics dominate the market share, while microbial sources lead in manufacturing capabilities. In terms of application, commercial manufacturing holds the largest share, and oncology is the leading therapeutic area, reflecting the high demand for cancer treatments.
To meet the rising demand for biopharmaceuticals, contract manufacturing organizations (CMOs) are increasingly adopting advanced technologies. Continuous manufacturing, for instance, is gaining traction as it allows for uninterrupted production of biologics, enhancing consistency, speed, and efficiency. This method significantly reduces downtime between production runs and minimizes the need for intermediate storage, leading to substantial cost savings. Reports suggest that continuous manufacturing can lower biological production costs by up to 30%. Major companies like Novartis and Pfizer are already implementing this technology to improve operational efficiency.
Automation is another critical advancement in the manufacturing process. By employing automated systems for tasks such as cell culture monitoring, chromatography, and aseptic filling, CMOs can accelerate production, reduce human error, and enhance quality control. Automation also aids in compliance with regulatory requirements by maintaining precise records and tracking each production stage. Samsung Biologics, for example, has heavily invested in automation to streamline its manufacturing processes and improve product quality, resulting in faster turnaround times for clients.
Artificial intelligence (AI) is also playing a transformative role in the biopharmaceutical manufacturing landscape. AI tools can analyze vast amounts of production data in real-time, enabling predictive maintenance and quality control. This technology helps CMOs identify potential issues before they escalate, ensuring optimal production conditions and minimizing downtime. Companies like Cognizant are leveraging AI to enhance decision-making and predict failures in manufacturing processes.
Moreover, the integration of process analytical technologies (PAT) allows for real-time monitoring and control of critical process parameters, ensuring consistent quality across large batches of biologics. By utilizing PAT, manufacturers can detect variations early in the production process and make necessary adjustments in real-time, leading to higher-quality products and more efficient resource utilization.
Geographically, South Africa is currently leading the market share in the region, driven by a growing demand for affordable biologics and government initiatives aimed at localizing pharmaceutical production. The partnership between the South African government and Biovac exemplifies efforts to enhance domestic manufacturing capacity and reduce reliance on imports. Opportunities for growth in South Africa include expanding capabilities for biosimilar production and fostering collaborations with global biopharma firms looking to enter the African market. For instance, Moderna's plans to establish an mRNA manufacturing facility in Africa underscore the region's increasing importance in the global biopharmaceutical supply chain.
Key players in the Middle East & Africa Biopharmaceutical Contract Manufacturing Market include Boehringer Ingelheim International GmbH, Lonza Group AG, AbbVie Inc, Samsung Biologics Co., Ltd., WuXi Biologics Inc, Merck KGaA, Ajinomoto Co., Inc., Cytiva, and AGC Biologics AS. These companies are actively pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and deliver innovative solutions to their clients.
The market is primarily segmented into key regions: the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa (MEA). Among these, the UAE and Saudi Arabia are at the forefront, showcasing robust infrastructure development and attracting substantial foreign direct investment. South Africa is also making strides through public-private partnerships, such as its collaboration with Biovac, a local vaccine manufacturer, which aims to bolster domestic production capabilities.
A notable trend in the biopharmaceutical contract manufacturing sector is the growing demand for biologics and biosimilars. As regional pharmaceutical companies face limitations in their in-house manufacturing capabilities, there is a marked shift towards outsourcing production to contract manufacturers. This outsourcing trend is further fueled by the increasing need for innovative therapies, including monoclonal antibodies, gene therapies, and cell-based treatments, which necessitate advanced manufacturing processes.
The market segmentation reveals that, by product type, biologics dominate the market share, while microbial sources lead in manufacturing capabilities. In terms of application, commercial manufacturing holds the largest share, and oncology is the leading therapeutic area, reflecting the high demand for cancer treatments.
To meet the rising demand for biopharmaceuticals, contract manufacturing organizations (CMOs) are increasingly adopting advanced technologies. Continuous manufacturing, for instance, is gaining traction as it allows for uninterrupted production of biologics, enhancing consistency, speed, and efficiency. This method significantly reduces downtime between production runs and minimizes the need for intermediate storage, leading to substantial cost savings. Reports suggest that continuous manufacturing can lower biological production costs by up to 30%. Major companies like Novartis and Pfizer are already implementing this technology to improve operational efficiency.
Automation is another critical advancement in the manufacturing process. By employing automated systems for tasks such as cell culture monitoring, chromatography, and aseptic filling, CMOs can accelerate production, reduce human error, and enhance quality control. Automation also aids in compliance with regulatory requirements by maintaining precise records and tracking each production stage. Samsung Biologics, for example, has heavily invested in automation to streamline its manufacturing processes and improve product quality, resulting in faster turnaround times for clients.
Artificial intelligence (AI) is also playing a transformative role in the biopharmaceutical manufacturing landscape. AI tools can analyze vast amounts of production data in real-time, enabling predictive maintenance and quality control. This technology helps CMOs identify potential issues before they escalate, ensuring optimal production conditions and minimizing downtime. Companies like Cognizant are leveraging AI to enhance decision-making and predict failures in manufacturing processes.
Moreover, the integration of process analytical technologies (PAT) allows for real-time monitoring and control of critical process parameters, ensuring consistent quality across large batches of biologics. By utilizing PAT, manufacturers can detect variations early in the production process and make necessary adjustments in real-time, leading to higher-quality products and more efficient resource utilization.
Geographically, South Africa is currently leading the market share in the region, driven by a growing demand for affordable biologics and government initiatives aimed at localizing pharmaceutical production. The partnership between the South African government and Biovac exemplifies efforts to enhance domestic manufacturing capacity and reduce reliance on imports. Opportunities for growth in South Africa include expanding capabilities for biosimilar production and fostering collaborations with global biopharma firms looking to enter the African market. For instance, Moderna's plans to establish an mRNA manufacturing facility in Africa underscore the region's increasing importance in the global biopharmaceutical supply chain.
Key players in the Middle East & Africa Biopharmaceutical Contract Manufacturing Market include Boehringer Ingelheim International GmbH, Lonza Group AG, AbbVie Inc, Samsung Biologics Co., Ltd., WuXi Biologics Inc, Merck KGaA, Ajinomoto Co., Inc., Cytiva, and AGC Biologics AS. These companies are actively pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and deliver innovative solutions to their clients.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET LANDSCAPE
4.1 PEST Analysis
5. MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - MIDDLE EAST & AFRICA MARKET ANALYSIS
6.1 Middle East & Africa Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
6.2 Middle East & Africa Biopharmaceutical Contract Manufacturing Market Forecast and Analysis
7. MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Biologics
7.1.1 Overview
7.1.2 Biologics: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Biosimilar
7.2.1 Overview
7.2.2 Biosimilar: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY SOURCE
8.1 Microbial
8.1.1 Overview
8.1.2 Microbial: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Mammalian
8.2.1 Overview
8.2.2 Mammalian: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY APPLICATION
9.1 Commercial
9.1.1 Overview
9.1.2 Commercial: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Clinical
9.2.1 Overview
9.2.2 Clinical: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY THERAPEUTIC AREA
10.1 Oncology
10.1.1 Overview
10.1.2 Oncology: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Autoimmune Disorders
10.2.1 Overview
10.2.2 Autoimmune Disorders: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Respiratory Disorders
10.3.1 Overview
10.3.2 Respiratory Disorders: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4 Metabolic Disorders
10.4.1 Overview
10.4.2 Metabolic Disorders: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.5 Neurology
10.5.1 Overview
10.5.2 Neurology: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.6 Infectious Diseases
10.6.1 Overview
10.6.2 Infectious Diseases: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.7 Others
10.7.1 Overview
10.7.2 Others: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - COUNTRY ANALYSIS
11.1 Middle East & Africa
11.1.1 Middle East & Africa Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.1.1 Middle East & Africa Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.2.2 Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.1.2.2.2 Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Source
11.1.2.2.3 Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Application
11.1.2.2.4 Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.2.3.3 South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.2.3.3.2 South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Source
11.2.3.3.3 South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Application
11.2.3.3.4 South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.3.4.4 United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.3.4.4.2 United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Source
11.3.4.4.3 United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Application
11.3.4.4.4 United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.4.5.5 Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4.5.5.1 Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.4.5.5.2 Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Source
11.4.5.5.3 Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Application
11.4.5.5.4 Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 Boehringer Ingelheim International GmbH
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Lonza Group AG
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 AbbVie Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Samsung Biologics Co Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 WuXi Biologics Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Ajinomoto Co Inc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Cytiva
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AGC Biologics AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET LANDSCAPE
4.1 PEST Analysis
5. MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - MIDDLE EAST & AFRICA MARKET ANALYSIS
6.1 Middle East & Africa Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
6.2 Middle East & Africa Biopharmaceutical Contract Manufacturing Market Forecast and Analysis
7. MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Biologics
7.1.1 Overview
7.1.2 Biologics: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Biosimilar
7.2.1 Overview
7.2.2 Biosimilar: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY SOURCE
8.1 Microbial
8.1.1 Overview
8.1.2 Microbial: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Mammalian
8.2.1 Overview
8.2.2 Mammalian: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY APPLICATION
9.1 Commercial
9.1.1 Overview
9.1.2 Commercial: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Clinical
9.2.1 Overview
9.2.2 Clinical: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY THERAPEUTIC AREA
10.1 Oncology
10.1.1 Overview
10.1.2 Oncology: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Autoimmune Disorders
10.2.1 Overview
10.2.2 Autoimmune Disorders: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Respiratory Disorders
10.3.1 Overview
10.3.2 Respiratory Disorders: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4 Metabolic Disorders
10.4.1 Overview
10.4.2 Metabolic Disorders: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.5 Neurology
10.5.1 Overview
10.5.2 Neurology: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.6 Infectious Diseases
10.6.1 Overview
10.6.2 Infectious Diseases: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.7 Others
10.7.1 Overview
10.7.2 Others: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - COUNTRY ANALYSIS
11.1 Middle East & Africa
11.1.1 Middle East & Africa Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.1.1 Middle East & Africa Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.2.2 Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.1.2.2.2 Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Source
11.1.2.2.3 Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Application
11.1.2.2.4 Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.2.3.3 South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.2.3.3.2 South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Source
11.2.3.3.3 South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Application
11.2.3.3.4 South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.3.4.4 United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.3.4.4.2 United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Source
11.3.4.4.3 United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Application
11.3.4.4.4 United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.4.5.5 Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4.5.5.1 Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.4.5.5.2 Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Source
11.4.5.5.3 Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Application
11.4.5.5.4 Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 Boehringer Ingelheim International GmbH
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Lonza Group AG
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 AbbVie Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Samsung Biologics Co Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 WuXi Biologics Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Ajinomoto Co Inc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Cytiva
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AGC Biologics AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
LIST OF TABLES
Table 1. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Segmentation
Table 3. Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 6. Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 7. Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 8. Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 10. Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 11. Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 12. Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 13. South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 14. South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 15. South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 16. South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 17. United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 18. United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 19. United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 20. United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 21. Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 22. Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 23. Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 25. Heat Map Analysis by Key Players
Table 1. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Segmentation
Table 3. Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 6. Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 7. Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 8. Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 10. Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 11. Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 12. Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 13. South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 14. South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 15. South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 16. South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 17. United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 18. United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 19. United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 20. United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 21. Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 22. Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 23. Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 25. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
Figure 7. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Biologics: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Biosimilar: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share (%) - by Source, 2024 and 2031
Figure 11. Microbial: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Mammalian: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share (%) - by Application, 2024 and 2031
Figure 14. Commercial: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Clinical: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share (%) - by Therapeutic Area, 2024 and 2031
Figure 17. Oncology: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Autoimmune Disorders: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Respiratory Disorders: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Metabolic Disorders: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Neurology: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Infectious Diseases: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Others: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 25. Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 29. Company Positioning & Concentration
Figure 1. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
Figure 7. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Biologics: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Biosimilar: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share (%) - by Source, 2024 and 2031
Figure 11. Microbial: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Mammalian: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share (%) - by Application, 2024 and 2031
Figure 14. Commercial: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Clinical: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Share (%) - by Therapeutic Area, 2024 and 2031
Figure 17. Oncology: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Autoimmune Disorders: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Respiratory Disorders: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Metabolic Disorders: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Neurology: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Infectious Diseases: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Others: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 25. Saudi Arabia: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. South Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. United Arab Emirates: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Rest of Middle East & Africa: Middle East & Africa Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 29. Company Positioning & Concentration
